Prestige Wealth Management Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Prestige Wealth Management Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-450	Closed	-$2K	–	1068
2021 Q2	$2K	Hold	450	–	–	﹤0.01%	842
2021 Q1	$2K	Hold	450	–	–	﹤0.01%	839
2020 Q4	$1K	Hold	450	–	–	﹤0.01%	915
2020 Q3	$1K	Sell	450 -4,000	-90%	-$14.7K	﹤0.01%	861
2020 Q2	$15K	Buy	4,450 +450	+11%	+$2.13K	0.01%	378
2020 Q1	$15K	Hold	4,000	–	–	0.01%	327
2019 Q4	$24K	Hold	4,000	–	–	0.01%	269
2019 Q3	$30K	Hold	4,000	–	–	0.02%	237
2019 Q2	$54K	Buy	+4,000	New	+$46.2K	0.03%	191

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prestige Wealth Management Group's ZYNE Position: Q3 2021 in Review

Prestige Wealth Management Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2021, closing a stake of 450 shares — an estimated $2K sold.

Prestige Wealth Management Group first reported a position in ZYNE in Q2 2019 and held it in 9 quarters. The position peaked at $54K in Q2 2019. 58 funds tracked by Wall St. Rank hold ZYNE as of Q3 2021.

Prestige Wealth Management Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
Prestige Wealth Management Group sold 450 Zynerba Pharmaceuticals, Inc shares in Q3 2021, an estimated $2K.
Prestige Wealth Management Group first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 9 quarters.
Prestige Wealth Management Group's Zynerba Pharmaceuticals, Inc position peaked at $54K in Q2 2019.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2021.

Based on Prestige Wealth Management Group's 13F filing for Q3 2021, filed 12 Nov 2021.